Cardiac Manifestations of Extracardiac Tumours—From an Oncologist’s Perspective †
Abstract
Introduction
Cardiac complications in a patient with Hodgkin lymphoma—a case report
Complications due to tumour invasion—cardiac metastases, direct tumour growth via vena cava veins
Cardiac metastases |
Neoplastic pericardial disease |
Superior vena cava syndrome |
Carcinoid heart disease |
Amyloid cardiomyopathy |
Drug-related cardiopathy |
Post-radiogenic cardiopathy |
Neoplastic pericardial disease
Complications due to tumour compression–superior vena cava syndrome
Complications due to paraneoplastic phenomena—carcinoid heart disease
Amyloid cardiomyopathy
Post-radiogenic cardiopathy
Conclusions
Acknowledgments
Funding/Potential Competing Interests
References
- Burke, A.; Virmani, R. Tumors of the Heart and Great Vessels; Atlas of tumor pathology, Ser 3; Armed Forces Institute of Pathology: Wahington, DC, USA, 1996. [Google Scholar]
- Reynen, K. Frequency of primary tumors of the heart. Am J Cardiol. 1996, 77, 107. [Google Scholar] [CrossRef] [PubMed]
- Bisel, H.F.; Wroblewski, F.; Ladue, J.S. Incidence and clinical manifestations of cardiac metastases. J Am Med Assoc. 1953, 153, 712–715. [Google Scholar] [CrossRef] [PubMed]
- Klatt, E.C.; Heitz, D.R. Cardiac metastases. Cancer. 1990, 65, 1456–1459. [Google Scholar] [CrossRef]
- Silvestri, F.; Bussani, R.; Pavletic, N.; Mannone, T. Metastases of the heart and pericardium. G Ital Cardiol. 1997, 27, 1252–1255. [Google Scholar]
- Deloach, J.F.; Haynes, J.W. Secondary tumors of heart and pericardium; review of the subject and report of one hundred thirty-seven cases. AMA Arch Intern Med. 1953, 91, 224–249. [Google Scholar] [CrossRef]
- Prichard, R.W. Tumors of the heart; review of the subject and report of 150 cases. AMA Arch Pathol. 1951, 51, 98–128. [Google Scholar]
- Glancy, D.L.; Roberts, W.C. The heart in malignant melanoma. A study of 70 autopsy cases. Am J Cardiol. 1968, 21, 555–571. [Google Scholar] [CrossRef]
- Bussani, R.; De-Giorgio, F.; Abbate, A.; Silvestri, F. Cardiac metastases. J Clin Pathol. 2007, 60, 27–34. [Google Scholar] [CrossRef]
- Chua, S.O.; Chiang, C.W.; Lee, Y.S.; Lin, S.H.; Liaw, Y.F. Moving right atrial mass associated with hepatoma. Two cases detected by echocardiography. Chest. 1986, 89, 148–150. [Google Scholar] [CrossRef]
- Van Camp, G.; Abdulsater, J.; Cosyns, B.; Liebens, I.; Vandenbossche, J.L. Transesophageal echocardiography of right atrial metastasis of a hepatocellular carcinoma. Chest. 1994, 105, 945–947. [Google Scholar] [CrossRef] [PubMed]
- Longo, R.; Mocini, D.; Santini, M.; Giannantoni, P.; Carillio, G.; Torino, F.; et al. Unusual sites of metastatic malignancy: Case 1. Cardiac metastasis in hepatocellular carcinoma. J Clin Oncol. 2004, 22, 5012–5014. [Google Scholar] [CrossRef]
- Atik, F.A.; Navia, J.L.; Krishnamurthi, V.; Singh, G.; Shiota, T.; Pitas, G.; et al. Solitary massive right ventricular metastasis of renal cell carcinoma without inferior vena cava or right atrium involvement. J Card Surg. 2006, 21, 304–306. [Google Scholar] [CrossRef]
- Aburto, J.; Bruckner, B.A.; Blackmon, S.H.; Beyer, E.A.; Reardon, M.J. Renal cell carcinoma, metastatic to the left ventricle. Tex Heart Inst J. 2009, 36, 48–49. [Google Scholar] [PubMed]
- Zayas, R.; Anguita, M.; Torres, F.; Giménez, D.; Bergillos, F.; Ruiz, M.; et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. Am J Cardiol. 1995, 75, 378–382. [Google Scholar] [CrossRef] [PubMed]
- Ben-Horin, S.; Bank, I.; Guetta, V.; Livneh, A. Large symptomatic pericardial effusion as the presentation of unrecognized cancer: A study in 173 consecutive patients undergoing pericardiocentesis. Medicine (Baltimore) 2006, 85, 49–53. [Google Scholar] [CrossRef] [PubMed]
- Little, W.C.; Freeman, G.L. Pericardial disease. Circulation. 2006, 113, 1622–1632. [Google Scholar] [CrossRef]
- Wilson, L.D.; Detterbeck, F.C.; Yahalom, J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007, 356, 1862–1869. [Google Scholar] [CrossRef]
- Ahmann, F.R. A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol. 1984, 2, 961–969. [Google Scholar] [CrossRef]
- Rice, T.W.; Rodriguez, R.M.; Light, R.W. The superior vena cava syndrome: Clinical characteristics and evolving etiology. Medicine (Baltimore). 2006, 85, 37–42. [Google Scholar] [CrossRef]
- Lundin, L.; Norheim, I.; Landelius, J.; Oberg, K.; Theodorsson-Norheim, E. Carcinoid heart disease: Relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation. 1988, 77, 264–269. [Google Scholar] [CrossRef]
- Roberts, W.C. A unique heart disease associated with a unique cancer: Carcinoid heart disease. Am J Cardiol. 1997, 80, 251–256. [Google Scholar] [CrossRef] [PubMed]
- Bernheim, A.M.; Connolly, H.M.; Pellikka, P.A. Carcinoid heart disease. Curr Treat Options Cardiovasc Med. 2007, 9, 482–489. [Google Scholar] [CrossRef] [PubMed]
- Gustafsson, B.I.; Hauso, O.; Drozdov, I.; Kidd, M.; Modlin, I.M. Carcinoid heart disease. Int J Cardiol. 2008, 129, 318–324. [Google Scholar] [CrossRef] [PubMed]
- Dero, I.; De Pauw, M.; Borbath, I.; Delaunoit, T.; Demetter, P.; Demolin, G.; et al. Carcinoid heart disease—a hidden complication of neuroendocrine tumours. Acta Gastroenterol Belg. 2009, 72, 34–38. [Google Scholar]
- Smith, S.A.; Waggoner, A.D.; de las Fuentes, L.; Davila-Roman, V.G. Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography. J Am Soc Echocardiogr. 2009, 22, 883–889, Epub 2009 Jun 23. [Google Scholar] [CrossRef]
- Dumoulein, M.; Verslype, C.; van Cutsem, E.; Meuris, B.; Herijgers, P.; Flameng, W.; Herregods, M.C. Carcinoid heart disease: Case and literature review. Acta Cardiol. 2010, 65, 261–264. [Google Scholar] [CrossRef]
- Bernheim, A.M.; Connolly, H.M.; Pellikka, P.A. Carcinoid heart disease in patients without hepatic metastases. Am J Cardiol. 2007, 99, 292–294. [Google Scholar] [CrossRef]
- Zuetenhorst, J.M.; Bonfrer, J.M.; Korse, C.M.; Bakker, R.; van Tinteren, H.; Taal, B.G. Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer. 2003, 97, 1609–1615. [Google Scholar] [CrossRef]
- Bhattacharyya, S.; Toumpanakis, C.; Chilkunda, D.; Caplin, M.E.; Davar, J. Risk Factors for the Development and Progression of Carcinoid Heart Disease. Am J Cardiol. 2011. [Google Scholar] [CrossRef]
- Dubrey, S.W.; Cha, K.; Simms, R.W.; Skinner, M.; Falk, R.H. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol. 1996, 77, 313–315. [Google Scholar] [CrossRef] [PubMed]
- Dubrey, S.W.; Cha, K.; Anderson, J.; Chamarthi, B.; Reisinger, J.; Skinner, M.; Falk, R.H. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998, 91, 141–157. [Google Scholar] [CrossRef]
- Falk, R.H.; Dubrey, S.W. Amyloid heart disease. Prog Cardiovasc Dis. 2010, 52, 347–361, Erratum in Prog Cardiovasc Dis. 2010, 52, 445–447. [Google Scholar] [CrossRef] [PubMed]
- Kyle, R.A.; Gertz, M.A.; Greipp, P.R.; Witzig, T.E.; Lust, J.A.; Lacy, M.Q.; Therneau, T.M. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997, 336, 1202–1207. [Google Scholar] [CrossRef] [PubMed]
- Wojnowski, L.; Kulle, B.; Schirmer, M.; Schlüter, G.; Schmidt, A.; Rosenberger, A.; et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005, 112, 3754–3762. [Google Scholar] [CrossRef] [PubMed]
- Berliner, S.; Rahima, M.; Sidi, Y.; Teplitsky, Y.; Zohar, Y.; Nussbaum, B.; Pinkhas, J. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest. 1990, 8, 583–586. [Google Scholar] [CrossRef]
- Paiva, C.E.; Michelin, O.C.; Okoshi, K. Acute Coronary Syndrome during Chemotherpy: Report of Three Cases. Revista Brasileira de Cancerologia. 2009, 55, 55–58. [Google Scholar] [CrossRef]
- Bovelli, D.; Plataniotis, G.; Roila, F.; ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010, 21 (Suppl. S5), v277–v282. [Google Scholar] [CrossRef]
- Chu, T.F.; Rupnick, M.A.; Kerkela, R.; Dallabrida, S.M.; Zurakowski, D.; Nguyen, L.; et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007, 370, 2011–2019. [Google Scholar] [CrossRef]
- Khakoo, A.Y.; Kassiotis, C.M.; Tannir, N.; Plana, J.C.; Halushka, M.; Bickford, C.; Trent, J., 2nd; Champion, J.C.; Durand, J.B.; Lenihan, D.J. Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008, 112, 2500–2508. [Google Scholar] [CrossRef]
Class | Drugs |
Anthracyclines | doxorubicin, daunorubicin, epirubicin, idarubicin |
Anthracycline-like drugs | Mitoxantrone |
Anti-metabolites | 5-fluoruracil, capecitabine, fludarabine, pentostatin, cladribine, methotrexate, cytarabine |
Vinca alkaloids and topoisomerase inhibitors | vincristine, vinblastine, vinorelbine, etoposide |
Taxanes | paclitaxel, docetaxel |
Alkylating agents | cyclophosphamide, ifosfa- mide, cisplatin, busulfan |
Anti-tumour antibiotics | bleomycin, mitomycin C |
Monoclonal antibodies | rituximab, bevacizumab, trastuzumab, alemtuzumab, cetuximab |
Cytokines | Interferon-alpha, Interleukin-2 |
Differentiation-inducing agents | all-trans retinoic acid (ATRA), arsenic trioxide |
Tyrosine kinase inhibitors | sorafenib, sunitinib, imatinib, nilotinib, dasatinib, lapatinib, pazopanib |
Other | vorinostat (histone deacetylase inhibitor) |
© 2011 by the author. Attribution - Non-Commercial - NoDerivatives 4.0.
Share and Cite
Hagner, N.M.; Cerny, T. Cardiac Manifestations of Extracardiac Tumours—From an Oncologist’s Perspective. Cardiovasc. Med. 2011, 14, 199. https://doi.org/10.4414/cvm.2011.01607
Hagner NM, Cerny T. Cardiac Manifestations of Extracardiac Tumours—From an Oncologist’s Perspective. Cardiovascular Medicine. 2011; 14(7):199. https://doi.org/10.4414/cvm.2011.01607
Chicago/Turabian StyleHagner, Nicole M., and Thomas Cerny. 2011. "Cardiac Manifestations of Extracardiac Tumours—From an Oncologist’s Perspective" Cardiovascular Medicine 14, no. 7: 199. https://doi.org/10.4414/cvm.2011.01607
APA StyleHagner, N. M., & Cerny, T. (2011). Cardiac Manifestations of Extracardiac Tumours—From an Oncologist’s Perspective. Cardiovascular Medicine, 14(7), 199. https://doi.org/10.4414/cvm.2011.01607